IMR Press / FBE / Volume 4 / Issue 6 / DOI: 10.2741/e542

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Modulation of normal and malignant plasma cells function by toll-like receptors

Show Less
1 INSERM, U866, 7 Boulevard Jeanne d’Arc, 21033 Dijon, France
2 University of Burgundy, Dijon, France
3 INSERM, U896, Nantes, France

Academic Editor: Isabelle Bekeredjian-Ding

Front. Biosci. (Elite Ed) 2012, 4(6), 2289–2301;
Published: 1 January 2012
(This article belongs to the Special Issue Exploiting toll-like receptors to interfere with the B cell response)

Toll-like receptors (TLRs) are well known activators of immune responses, but their involvement in the plasma cell (PC) differentiation process remains mostly unknown. This review is focused on the expression and function of TLRs on normal PCs and their malignant counterpart, Multiple Myeloma cells. We report studies that suggest a role for TLR ligands as adjuvants of the humoral immune response through the survival of newly generated immature PCs. On the contrary, TLRs do not seem to be involved in the long-term maintenance of PCs in the bone marrow. Multiple Myeloma cells express a broad range of TLRs, and show heterogeneous responses to different ligands. These double-edged-sword effects are presented and discussed in the context of tumor progression, and as putative therapeutic targets.

Toll-like receptor
Multiple myeloma
Back to top